Upregulation of Notch2 and Six1 is associated with progression of early-stage lung adenocarcinoma and a more aggressive phenotype at advanced stages

Clinical Cancer Research

Volumn 18, Issue 4, 2012, Pages 945-955

  Mimae, Takahiro ^a,b   Okada, Morihito ^a   Hagiyama, Man ^b,c   Miyata, Yoshihiro ^a   Tsutani, Yasuhiro ^a   Inoue, Takao ^c   Murakami, Yoshinori ^b   Ito, Akihiko ^c  

^a HIROSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KINKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH2 RECEPTOR; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSCRIPTION FACTOR SIX1; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CARCINOMA CELL; CELL NUCLEUS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC SCREENING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; TRANSACTIVATION; TRANSCRIPTION REGULATION;

ADENOCARCINOMA; CELL LINE, TUMOR; DISEASE PROGRESSION; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHENOTYPE; RECEPTOR, NOTCH2; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84857070517     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1946     Document Type: Article

References (42)

1. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005;117:294-9. (Pubitemid 41379403)
2. Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008;32:810-27.
3. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/ American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-85.
4. Aoyagi Y, Yokose T, Minami Y, Ochiai A, Iijima T, Morishita Y, et al. Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma. Cancer Res 2001;61:7950-4. (Pubitemid 33049386)
5. Aviel-Ronen S, Coe BP, Lau SK, da Cunha Santos G, Zhu CQ, Strumpf D, et al. Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. Proc Natl Acad Sci U S A 2008;105:10155-60.
6. Seki N, Takasu T, Mandai K, Nakata M, Saeki H, Heike Y, et al. Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clin Cancer Res 2002;8:3046-53. (Pubitemid 35155013)
7. Soh J, Toyooka S, Ichihara S, Asano H, Kobayashi N, Suehisa H, et al. Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J Thorac Oncol 2008;3:340-7. (Pubitemid 351489472)
8. Morishita Y, Fukasawa M, Takeuchi M, Inadome Y, Matsuno Y, Noguchi M. Small-sized adenocarcinoma of the lung. Cytologic characteristics and clinical behavior. Cancer 2001;93:124-31. (Pubitemid 32322167)
9. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995;75:2844-52.
10. Maezawa N, Tsuta K, Shibuki Y, Yamazaki S, Maeshima AM, Watanabe S, et al. Cytopathologic factors can predict invasion in smallsized peripheral lung adenocarcinoma with a bronchioloalveolar carcinoma component. Cancer 2006;108:488-93. (Pubitemid 46076969)
11. Terasaki H, Niki T, Matsuno Y, Yamada T, Maeshima A, Asamura H, et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol 2003;27:937-51. (Pubitemid 36758897)
12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. (Pubitemid 38637993)
13. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. (Pubitemid 38720929)
14. Sakamoto H, Shimizu J, Horio Y, Ueda R, Takahashi T, Mitsudomi T, et al. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFRgene mutation from preinvasive to invasive adenocarcinomas. J Pathol 2007;212:287-94. (Pubitemid 47010062)
15. Westra WH, Baas IO, Hruban RH, Askin FB, Wilson K, Offerhaus GJ, et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 1996;56:2224-8. (Pubitemid 26119929)
16. Yatabe Y, Takahashi T, Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res 2008;68: 2106-11. (Pubitemid 351521782)
17. Tang ZQ, Han LY, Lin HH, Cui J, Jia J, LowBC, et al. Derivation of stable microarray cancer-differentiating signatures using consensus scoring of multiple random sampling and gene-ranking consistency evaluation. Cancer Res 2007;67:9996-10003. (Pubitemid 47621250)
18. Zhang HJ, Wang HY, Zhang HT, Su JM, Zhu J, Wang HB, et al. Transforming growth factor-beta1 promotes lung adenocarcinoma invasion and metastasis by epithelial-to-mesenchymal transition. Mol Cell Biochem 2011;355:309-14.
19. Shih JY, Yang PC. The EMT regulator slug and lung carcinogenesis. Carcinogenesis 2011;32:1299-304.
20. Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 2010;70: 10433-44.
21. Li C, Cai J, Pan Q, Minoo P. Two functionally distinct forms of NKX2.1 protein are expressed in the pulmonary epithelium. Biochem Biophys Res Commun 2000;270:462-8. (Pubitemid 30446859)
22. Akagi T, Murata K, Shishido T, Hanafusa H. v-Crk activates the phosphoinositide 3-kinase/AKT pathway by utilizing focal adhesion kinase and H-Ras. Mol Cell Biol 2002;22:7015-23.
23. GEO Browser [Internet]. Bethesda (MD): National Library of Medicine (US); 2002. Expression profiling by array [cited 2011 Jul 14]. Available from: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=plkbnogawiamexw& acc=GSE30663 Accession Number: GSE30663.
24. Bessarab DA, Chong SW, Korzh V. Expression of zebrafish six1 during sensory organ development and myogenesis. Dev Dyn 2004;230: 781-6. (Pubitemid 38993877)
25. Rodriguez S, Sickles HM, Deleonardis C, Alcaraz A, Gridley T, Lin DM. Notch2 is required for maintaining sustentacular cell function in the adult mouse main olfactory epithelium. Dev Biol 2008;314:40-58.
26. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell 2009;16:633-47.
27. Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Baron AE, Harrell JC, et al. The Six1 homeoprotein induces humanmammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest 2009; 119:2678-90.
28. Tang Y, Urs S, Boucher J, Bernaiche T, Venkatesh D, Spicer DB, et al. Notch and transforming growth factor-beta (TGFbeta) signaling pathways cooperatively regulate vascular smooth muscle cell differentiation. J Biol Chem 2010;285:17556-63.
29. Kida Y, Maeda Y, Shiraishi T, Suzuki T, Ogura T. Chick Dach1 interacts with the Smad complex and Sin3a to control AER formation and limb development along the proximodistal axis. Development 2004; 131:4179-87. (Pubitemid 39276188)
30. Grego-Bessa J, Diez J, Timmerman L, de la Pompa JL. Notch and epithelial-mesenchyme transition in development and tumor progression: another turn of the screw. Cell Cycle 2004;3:718-21. (Pubitemid 40187897)
31. Weinmaster G, Roberts VJ, Lemke G. A homolog of Drosophila Notch expressed during mammalian development. Development 1991; 113:199-205.
32. Jadhav AP, Mason HA, Cepko CL. Notch 1 inhibits photoreceptor production in the developing mammalian retina. Development 2006; 133:913-23.
33. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-6. (Pubitemid 29291335)
34. Collins BJ, Kleeberger W, Ball DW. Notch in lung development and lung cancer. Semin Cancer Biol 2004;14:357-64. (Pubitemid 38993637)
35. Konishi J, Kawaguchi KS, Vo H, Haruki N, Gonzalez A, Carbone DP, et al. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 2007; 67:8051-7. (Pubitemid 47395139)
36. Ji X, Wang Z, Geamanu A, Sarkar FH, Gupta SV. Inhibition of cell growth and induction of apoptosis in non-small cell lung cancer cells by delta-tocotrienol is associated with Notch-1 down-regulation. J Cell Biochem 2011;112:2773-83.
37. Levine M, Hoey T. Homeobox proteins as sequence-specific transcription factors. Cell 1988;55:537-40.
38. Coletta RD, Christensen K, Reichenberger KJ, Lamb J, Micomonaco D, Huang L, et al. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci U S A 2004;101:6478-83. (Pubitemid 38585999)
39. Coletta RD, Christensen KL, Micalizzi DS, Jedlicka P, Varella-Garcia M, Ford HL. Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. Cancer Res 2008;68:2204-13. (Pubitemid 351521793)
40. Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R, Ford HL. Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-beta signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene 2011; Jun 27 [Epub ahead of print].
41. Anami Y, Iijima T, Suzuki K, Yokota J, Minami Y, Kobayashi H, et al. Bronchioloalveolar carcinoma (lepidic growth) component is a more useful prognostic factor than lymph node metastasis. J Thorac Oncol 2009;4:951-8.
42. Colice GL, Rubins J, Unger MAmerican College of Chest P. Follow-up and surveillance of the lung cancer patient following curative-intent therapy. Chest 2003;123:272S-83S. (Pubitemid 36135722)